Vyome Holdings, Inc.
HINDHealthcare|Biotechnology|US
$1.58
-0.05 (-3.07%)
DCF Value
$1.87
Tangible Book / Share
$1.00
Cash / Share
$1.12
About
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
Stock Price
-72.1%(1Y)
1M
-22.2%
3M
-26.9%
6M
-23.3%
YTD
-54.1%
1Y
-71.0%
3Y
-99.9%
5Y
-100.0%
Pipeline Summary
1 total trials0
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
Unknown: 1
Key Facts
Market Cap$11.1M
Employees9 (-47% YoY)
CEOVenkateswarlu Nelabhotla
IPO DateOct 6, 2016
Beta1.51
52-Week Range$1.57 – $5.88
Avg Volume13,460
ExchangeNASDAQ
Websitevyometx.com
Ownership
Float28.8%
Shares Outstanding7.0M
Recent Insider Trades
Jolly MohanjitAWARD
Sep 1, 2026120,000 shares @ $2.17
Leonard JerryOTHER
Sep 1, 20260 shares
Pomichter Stanley D IIIAWARD
Nov 13, 202517,833 shares @ $0.66
Pomichter Stanley D IIIOTHER
Aug 15, 20250 shares
Jolly MohanjitAWARD
Aug 15, 2025454,456 shares
Peers
Recent News
Vyome Co-Founder Dr. Shiladitya Sengupta Promoted to Professor at Harvard Medical School
Oct 26, 2026 · businesswire.com
Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market
Oct 5, 2026 · businesswire.com
Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer
Sep 14, 2026 · businesswire.com
Data last updated: Nov 9, 2026, 04:13 AM